Celerion acquires early stage clinical research operations from MDS Pharma Services – Celerion #biggest #pharmaceutical #companies

Posted On Dec 6 2017 by

#mds pharma services # Celerion acquires early stage clinical research operations from MDS Pharma Services Celerion acquires early stage clinical research operations from MDS Pharma Services (Lincoln, NE, Mar 29, 2010) – Celerion, a privately owned contract research organization (CRO), has completed the acquisition of the development and regulatory services consultancy and early stage development operations of MDS Pharma Services. The acquired assets include five clinical research facilities and two bioanalytical laboratories located in Lincoln, Nebraska; Neptune, New Jersey; Phoenix, Arizona; Zurich, Switzerland; and Belfast, Northern Ireland, as well as operations in Richmond, Virginia and Quebec, Canada. With over 700 …


Lupin Acquires Branded Product Portfolio from Shionogi in Japan #pharma #chemie

Posted On Dec 1 2017 by

#shionogi pharma # Lupin Acquires Branded Product Portfolio from Shionogi in Japan Mumbai, India and Osaka, Japan August 02, 2016: Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co. Ltd. (Head Office: Osaka, Japan; President Representative Director: Ray Tsunoda; hereafter “Kyowa”) has entered into a strategic asset purchase agreement with Shionogi Co. Ltd. (Head Office: Osaka, Japan; President CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”), on August 1, 2016, to acquire 21 long-listed products from the Japanese pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing …


Celerion acquires early stage clinical research operations from MDS Pharma Services – Celerion #dusa #pharma

Posted On Nov 27 2017 by

#mds pharma services # Celerion acquires early stage clinical research operations from MDS Pharma Services Celerion acquires early stage clinical research operations from MDS Pharma Services (Lincoln, NE, Mar 29, 2010) – Celerion, a privately owned contract research organization (CRO), has completed the acquisition of the development and regulatory services consultancy and early stage development operations of MDS Pharma Services. The acquired assets include five clinical research facilities and two bioanalytical laboratories located in Lincoln, Nebraska; Neptune, New Jersey; Phoenix, Arizona; Zurich, Switzerland; and Belfast, Northern Ireland, as well as operations in Richmond, Virginia and Quebec, Canada. With over 700 …


Lupin Acquires Branded Product Portfolio from Shionogi in Japan #jobs #in #pharmaceuticals

Posted On Nov 14 2017 by

#shionogi pharma # Lupin Acquires Branded Product Portfolio from Shionogi in Japan Mumbai, India and Osaka, Japan August 02, 2016: Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co. Ltd. (Head Office: Osaka, Japan; President Representative Director: Ray Tsunoda; hereafter “Kyowa”) has entered into a strategic asset purchase agreement with Shionogi Co. Ltd. (Head Office: Osaka, Japan; President CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”), on August 1, 2016, to acquire 21 long-listed products from the Japanese pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing …


Lupin Acquires Branded Product Portfolio from Shionogi in Japan #pharmaceutical #manufacturing

Posted On Sep 7 2017 by

#shionogi pharma # Lupin Acquires Branded Product Portfolio from Shionogi in Japan Mumbai, India and Osaka, Japan August 02, 2016: Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co. Ltd. (Head Office: Osaka, Japan; President Representative Director: Ray Tsunoda; hereafter “Kyowa”) has entered into a strategic asset purchase agreement with Shionogi Co. Ltd. (Head Office: Osaka, Japan; President CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”), on August 1, 2016, to acquire 21 long-listed products from the Japanese pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing …


Celerion acquires early stage clinical research operations from MDS Pharma Services – Celerion #par #pharma

Posted On Sep 1 2017 by

#mds pharma services # Celerion acquires early stage clinical research operations from MDS Pharma Services Celerion acquires early stage clinical research operations from MDS Pharma Services (Lincoln, NE, Mar 29, 2010) – Celerion, a privately owned contract research organization (CRO), has completed the acquisition of the development and regulatory services consultancy and early stage development operations of MDS Pharma Services. The acquired assets include five clinical research facilities and two bioanalytical laboratories located in Lincoln, Nebraska; Neptune, New Jersey; Phoenix, Arizona; Zurich, Switzerland; and Belfast, Northern Ireland, as well as operations in Richmond, Virginia and Quebec, Canada. With over 700 …


Celerion acquires early stage clinical research operations from MDS Pharma Services – Celerion #pharma #etf

Posted On Aug 12 2017 by

#mds pharma services # Celerion acquires early stage clinical research operations from MDS Pharma Services Celerion acquires early stage clinical research operations from MDS Pharma Services (Lincoln, NE, Mar 29, 2010) – Celerion, a privately owned contract research organization (CRO), has completed the acquisition of the development and regulatory services consultancy and early stage development operations of MDS Pharma Services. The acquired assets include five clinical research facilities and two bioanalytical laboratories located in Lincoln, Nebraska; Neptune, New Jersey; Phoenix, Arizona; Zurich, Switzerland; and Belfast, Northern Ireland, as well as operations in Richmond, Virginia and Quebec, Canada. With over 700 …


Lupin Acquires Branded Product Portfolio from Shionogi in Japan #small #pharma #companies

Posted On Aug 2 2017 by

#shionogi pharma # Lupin Acquires Branded Product Portfolio from Shionogi in Japan Mumbai, India and Osaka, Japan August 02, 2016: Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co. Ltd. (Head Office: Osaka, Japan; President Representative Director: Ray Tsunoda; hereafter “Kyowa”) has entered into a strategic asset purchase agreement with Shionogi Co. Ltd. (Head Office: Osaka, Japan; President CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”), on August 1, 2016, to acquire 21 long-listed products from the Japanese pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing …


Lupin Acquires Branded Product Portfolio from Shionogi in Japan #pharma #packaging

Posted On Jul 23 2017 by

#shionogi pharma # Lupin Acquires Branded Product Portfolio from Shionogi in Japan Mumbai, India and Osaka, Japan August 02, 2016: Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co. Ltd. (Head Office: Osaka, Japan; President Representative Director: Ray Tsunoda; hereafter “Kyowa”) has entered into a strategic asset purchase agreement with Shionogi Co. Ltd. (Head Office: Osaka, Japan; President CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”), on August 1, 2016, to acquire 21 long-listed products from the Japanese pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing …


Aton Pharma Acquires U #sun #pharma #india

Posted On Jul 12 2017 by

#aton pharma # Aton Pharma Acquires U.S. TIMOPTIC(R) LAWRENCEVILLE, N.J. Feb. 25 /PRNewswire/ — Aton Pharma, Inc. a diversified specialty pharmaceutical company, today announced it has acquired the U.S. marketing rights to the TIMOPTIC(R) product line from Merck Co. Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma. The U.S. TIMOPTIC product line includes TIMOPTIC(R) (timolol maleate) Ophthalmic Solution, TIMOPTIC (timolol maleate ophthalmic solution) in OCUDOSE(R) (sterile ophthalmic unit dose dispenser) and …